Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02NNV
|
|||
| Former ID |
DCL000261
|
|||
| Drug Name |
VX-745
|
|||
| Synonyms |
5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 209410-46-8; Neflamapimod; VX 745; VX745; VRT-031745; UNII-TYL52QM320; TYL52QM320; CHEBI:90528; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; Neflamapimod (USAN); Neflamapimod [USAN]; AK-44905; C19H9Cl2F2N3OS; 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One; VX745, VX-745; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; Vertex 745 (VX745)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1], [2] | |
| Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [3], [4], [5] | ||
| Company |
Vertex Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H9Cl2F2N3OS
|
|||
| Canonical SMILES |
C1=CC(=C(C(=C1)Cl)C2=C3C=CC(=NN3C=NC2=O)SC4=C(C=C(C=C4)F)F)Cl
|
|||
| InChI |
1S/C19H9Cl2F2N3OS/c20-11-2-1-3-12(21)17(11)18-14-5-7-16(25-26(14)9-24-19(18)27)28-15-6-4-10(22)8-13(15)23/h1-9H
|
|||
| InChIKey |
VEPKQEUBKLEPRA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 209410-46-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10049048, 14905671, 36106235, 46515551, 50100122, 50743824, 58670187, 85173223, 92719271, 93310134, 96022677, 99008617, 99437163, 99443609, 103344166, 103905630, 111646289, 118310938, 123051103, 124757265, 124950172, 125164069, 125344707, 126628288, 126651678, 126670738, 131305005, 131480883, 132048641, 134224254, 134338918, 134340669, 135141968, 136024966, 136340276, 136349964, 136367430, 136367729, 136378069, 140238366, 143497599, 152212967, 152239272, 152258175, 152344370, 160647012, 160812759, 160968223, 162011807, 162191904
|
|||
| ChEBI ID |
CHEBI:90528
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5719). | |||
| REF 4 | ClinicalTrials.gov (NCT02423200) Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD. U.S. National Institutes of Health. | |||
| REF 5 | Myelodysplastic Syndromes: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2011 January; 9(1): 30-56. | |||
| REF 6 | P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm (Lond). 2008 Dec 4;5:22. | |||
| REF 7 | Rapid synthesis of VX-745: p38 MAP kinase inhibition in Werner syndrome cells. Bioorg Med Chem Lett. 2007 Sep 15;17(18):5107-10. | |||
| REF 8 | Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.